COMMUNIQUÉS West-GlobeNewswire

Thousands of State of Georgia employees walk 880 million steps to benefit Title I schools
30/09/2025
State Health Benefit Plan members come together to help young Georgians in their communities while improving their personal health ‘Jump Shot for Health’ awards winning schools new sports equipment and renovated [...]
Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes
30/09/2025
Collaboration leverages Parexel's proven regulatory expertise and Weave Bio's AI-native platform, aims to speed up market introduction of new therapies RALEIGH, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Parexel, a [...]
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
30/09/2025
Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in manufacturability, [...]
24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs
30/09/2025
DENVER, Sept. 30, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, highlights the opportunity for recombinant spider [...]
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
30/09/2025
Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, [...]
Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
30/09/2025
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Prenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore
30/09/2025
- Keynote: “IM8: The World’s Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury - Prenetics currently holds 246 BTC with a NAV of $28M - Prenetics has $63.5m of cash 1 CHARLOTTE, N.C., Sept. 30, 2025 (GLOBE [...]
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
30/09/2025
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), [...]
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
30/09/2025
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only [...]
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
30/09/2025
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced [...]
AssistRx Joins Second Annual Drug Channels Leadership Forum as Diamond Sponsor
30/09/2025
Invite-only event will address today’s most pressing healthcare system challenges ORLANDO, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation and patient solutions provider, today [...]
Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies
30/09/2025
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug [...]
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
30/09/2025
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 [...]
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
30/09/2025
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto
30/09/2025
Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the successful closing of a $41 million private investment in public equity (PIPE [...]
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
30/09/2025
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2 clinical trial in patients with cognitive impairment associated with schizophrenia [...]
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
30/09/2025
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses observed out to 18 [...]
Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings
30/09/2025
NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance [...]
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
30/09/2025
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the [...]

Pages